<?xml version="1.0" encoding="UTF-8"?>
<ref id="B51">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mesu</surname>
    <given-names>V. K. B. Ku</given-names>
   </name>
   <name>
    <surname>Kalonji</surname>
    <given-names>W. M.</given-names>
   </name>
   <name>
    <surname>Bardonneau</surname>
    <given-names>Clélia</given-names>
   </name>
   <name>
    <surname>Valverde Mordt</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Blesson</surname>
    <given-names>Séverine</given-names>
   </name>
   <name>
    <surname>Simon</surname>
    <given-names>François</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2018</year>). 
  <article-title>Oral Fexinidazole for Late-Stage African Trypanosoma Brucei Gambiense Trypanosomiasis: A Pivotal Multicentre, Randomised, Non-Inferiority Trial</article-title>. 
  <source>Lancet (London England)</source>
  <volume>391</volume> (
  <issue>10116</issue>), 
  <fpage>144</fpage>–
  <lpage>154</lpage>.  
  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32758-7</pub-id>
 </mixed-citation>
</ref>
